Adoptive-cell-transfer therapy for the treatment of patients with cancer
about
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cellsAdoptive immunotherapy for cancer: building on successAdoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanomaAdoptive T cell therapy: Addressing challenges in cancer immunotherapyEngineering approaches for regeneration of T lymphopoiesisChimeric Antigen Receptors Modified T-Cells for Cancer TherapyAdoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlookHLA Class I Restriction as a Possible Driving Force for Chikungunya EvolutionImproving cell-based therapies by nanomodificationImmunotherapy for Bone and Soft Tissue SarcomasRestoring function in exhausted CD8 T cells during chronic viral infectionAdoptive transfer of Mammaglobin-A epitope specific CD8 T cells combined with a single low dose of total body irradiation eradicates breast tumorsImmunosuppressive strategies that are mediated by tumor cellsThe antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status.IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes.Proteomics in cancer vaccine development.Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts.Engineering higher affinity T cell receptors using a T cell display system.Re-adapting T cells for cancer therapy: from mouse models to clinical trials.CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissuesIncubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2Genome-Edited T Cell Therapies.HCV T Cell Receptor Chain Modifications to Enhance Expression, Pairing, and Antigen Recognition in T Cells for Adoptive Transfer.Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinomaClosely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15Genomic analysis of CD8+ NK/T cell line, 'SRIK-NKL', with array-based CGH (aCGH), SKY/FISH and molecular mapping.Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cellsA critical role for virus-specific CD8(+) CTLs in protection from Theiler's virus-induced demyelination in disease-susceptible SJL mice.CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.Comparison of human memory CD8 T cell responses to adenoviral early and late proteins in peripheral blood and lymphoid tissue.Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells.The duplicitous effects of interleukin 4 on tumour immunity: how can the same cytokine improve or impair control of tumour growth?Antiproliferative Properties of Type I and Type II Interferon.Strategies to overcome obstacles to successful immunotherapy of melanomaPhosphorylcholine-coated semiconducting polymer nanoparticles as rapid and efficient labeling agents for in vivo cell trackingCD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.Antigen quality determines the efficiency of antitumor immune responses generated in the absence of regulatory T cellsCell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles.Antibody-based immunotherapy for malignant glioma.
P2860
Q24530100-277DAB99-6B9F-4024-9727-066559CA6CFFQ24546258-A6688615-026D-4C01-A708-AFF0C354CDDFQ24548019-AE05E611-75A6-4230-B074-C72E8558CACCQ24805804-ED06505E-AB88-48FC-BF38-FB5028BDB44FQ26745978-FDCB6E14-92BD-4549-ADC8-5CBA4EED7C5BQ26773309-7B999E62-CBB6-4EFB-AF20-CEAFA3FD0B54Q27004178-F208B060-0400-4518-99A7-B6E66407E9F3Q27490985-6A4D30F5-FFF7-41E7-9FFC-CFCF0C02DE24Q28080427-3ADE8F2E-90C3-4C27-BD7B-7DEF54843792Q28088363-2CECAE82-CE2E-49AD-A41E-34574B106120Q28289222-6FF3ABCC-13B3-4219-B7D2-940F3FE4E6D2Q28386603-2442A2F1-321C-4A2F-AD1F-6C877ED6E3C4Q29636247-9C0617E1-1DB8-4CC1-B3C4-4D7C0E8FBFBDQ30252521-931B782B-585E-43D2-A4D5-D963A76EE608Q30481064-D7BFF316-F265-4F6B-A4EE-BF74C3FCFB75Q33215044-29A5714C-5D1B-4BC7-AAFA-A3904E3F7BF6Q33261122-562C2153-8BB4-43C6-A008-C59E980043ECQ33357299-5199971F-28F3-4AD3-86C4-050603476CD8Q33375887-775119F1-6CA3-4794-A239-459DF7AC8793Q33588711-46FB3DAC-62FE-42A1-AF29-23B35DAE19ABQ33615216-424D9D7B-8772-4808-BEE0-89F906CF922EQ33680751-F842459B-96F3-4C44-A0C3-40606A7F0D54Q33729598-8D7BE65D-005F-493C-9702-3E5AF33BEF8CQ33735871-C58384E2-2181-40F6-87AC-5F9AD3B1C5A5Q33738279-DFED93BE-24B8-44CC-960B-AFBF9C4AFA93Q33749635-5A316C23-F44E-4B03-8C15-33D537043816Q33793137-EFD9540F-BAC1-4916-80F7-DA4591B63204Q33831940-1EC3FDD7-FA2E-4422-ACC5-8852ADF023FFQ33857396-58E9BD87-A1BA-4573-A6E1-8BB32BFC6C10Q33867018-79F73775-45C3-4516-B74D-F7DD67B7307BQ33921073-FDA818D5-38A8-4342-A4A6-0DFB4A16E7A2Q33928413-B39EDF9A-D987-4D6A-8A25-3CD4D837729FQ34003186-399F721F-35C6-4166-817C-72E4904BEB33Q34007700-D161A8B4-72D4-4990-87B6-3763FE833F6EQ34042968-878CBAD0-0F00-4587-9CA8-58C6FD7DEE50Q34052926-7E40F22B-5C26-4C64-95C5-D3961F0C9930Q34063120-F5125C73-4546-4AEF-8CC7-C3D2935C69D1Q34076126-0A65E94D-107C-42DA-9A54-2401A97EF7ADQ34079604-673229CA-352B-4B32-A27D-6F1AAF44FD63Q34120472-A993B3CA-2739-48DF-9B3C-23A41A350ECC
P2860
Adoptive-cell-transfer therapy for the treatment of patients with cancer
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Adoptive-cell-transfer therapy for the treatment of patients with cancer
@ast
Adoptive-cell-transfer therapy for the treatment of patients with cancer
@en
type
label
Adoptive-cell-transfer therapy for the treatment of patients with cancer
@ast
Adoptive-cell-transfer therapy for the treatment of patients with cancer
@en
prefLabel
Adoptive-cell-transfer therapy for the treatment of patients with cancer
@ast
Adoptive-cell-transfer therapy for the treatment of patients with cancer
@en
P2860
P356
P1476
Adoptive-cell-transfer therapy for the treatment of patients with cancer
@en
P2093
Mark E Dudley
Steven A Rosenberg
P2860
P2888
P304
P356
10.1038/NRC1167
P407
P577
2003-09-01T00:00:00Z
P5875
P6179
1050453214